These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20586686)

  • 21. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder.
    McElroy SL; Bowden CL; Collins MA; Wozniak PJ; Keck PE; Calabrese JR
    J Affect Disord; 2008 Apr; 107(1-3):127-33. PubMed ID: 17888516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone for maintenance treatment of bipolar I disorder in adults.
    Dubovsky SL; Dubovsky AN
    Expert Opin Pharmacother; 2011 Apr; 12(5):817-24. PubMed ID: 21385150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review.
    Sacchetti E; Galluzzo A; Valsecchi P
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):163-79. PubMed ID: 22115400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144).
    Nolen WA; Weisler RH
    Bipolar Disord; 2013 Feb; 15(1):100-9. PubMed ID: 23228201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
    McIntyre RS; Konarski JZ; Jones M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
    Bowden CL; Calabrese JR; Sachs G; Yatham LN; Asghar SA; Hompland M; Montgomery P; Earl N; Smoot TM; DeVeaugh-Geiss J;
    Arch Gen Psychiatry; 2003 Apr; 60(4):392-400. PubMed ID: 12695317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
    Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
    Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive treatment of acute mania: a clinical overview.
    Sachs GS; Gardner-Schuster EE
    Acta Psychiatr Scand Suppl; 2007; (434):27-34. PubMed ID: 17688460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis.
    Lindström L; Lindström E; Nilsson M; Höistad M
    J Affect Disord; 2017 Apr; 213():138-150. PubMed ID: 28222360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.
    Quiroz JA; Yatham LN; Palumbo JM; Karcher K; Kushner S; Kusumakar V
    Biol Psychiatry; 2010 Jul; 68(2):156-62. PubMed ID: 20227682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).
    Carlson BX; Ketter TA; Sun W; Timko K; McQuade RD; Sanchez R; Vester-Blokland E; Marcus R
    Bipolar Disord; 2012 Feb; 14(1):41-53. PubMed ID: 22329471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
    Pappadopulos E; Newcomer JW; Kolluri S
    J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
    Lee HB; Yoon BH; Kwon YJ; Woo YS; Lee JG; Kim MD; Bahk WM
    Clin Drug Investig; 2013 Oct; 33(10):743-53. PubMed ID: 23990283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study.
    Lohoff FW; Etemad B; Mandos LA; Gallop R; Rickels K
    J Clin Psychopharmacol; 2010 Apr; 30(2):185-9. PubMed ID: 20520293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles.
    Kemp DE; Karayal ON; Calabrese JR; Sachs GS; Pappadopulos E; Ice KS; Siu CO; Vieta E
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):123-31. PubMed ID: 21798721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.
    Patkar AA; Pae CU; Vöhringer PA; Mauer S; Narasimhan M; Dalley S; Loebel A; Masand PS; Ghaemi SN
    J Clin Psychopharmacol; 2015 Jun; 35(3):319-23. PubMed ID: 25882763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Ketter TA; Cucchiaro J; Loebel A
    J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
    Fajutrao L; Paulsson B; Liu S; Locklear J
    Clin Ther; 2009 Jun; 31 Pt 1():1456-68. PubMed ID: 19698903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone.
    Karayal ON; Anway SD; Batzar E; Vanderburg DG
    J Clin Psychiatry; 2011 Mar; 72(3):367-75. PubMed ID: 21450154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving and sustaining remission in bipolar I disorder with ziprasidone : a post hoc analysis of a 24-week, double-blind, placebo-controlled study.
    Pae CU; Masand PS; Mandel FS; O'Gorman C
    Clin Drug Investig; 2012 Nov; 32(11):747-54. PubMed ID: 23026845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.